Diabetes Metab J.  2023 Jul;47(4):571-572. 10.4093/dmj.2023.0164.

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)

• Ko J
• Moon SJ

• KMID: 2544735
• DOI: http://doi.org/10.4093/dmj.2023.0164

Reference

1. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017; 5:431–7.

2. Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ, et al. Risk of diabetic retinopathy between sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists. Diabetes Metab J. 2023; 47:394–404.

3. Ding J, Wong TY. Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep. 2012; 12:346–54.

4. Ahmad E, Lim S, Lamptey R, Webb DR, Davies MJ. Type 2 diabetes. Lancet. 2022; 400:1803–20.

5. Sabanayagam C, Banu R, Chee ML, Lee R, Wang YX, Tan G, et al. Incidence and progression of diabetic retinopathy: a systematic review. Lancet Diabetes Endocrinol. 2019; 7:140–9.

6. Li C, Zhou Z, Neuen BL, Yu J, Huang Y, Young T, et al. Sodiumglucose co-transporter-2 inhibition and ocular outcomes in patients with type 2 diabetes: a systematic review and metaanalysis. Diabetes Obes Metab. 2021; 23:252–7.